These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 3141083

  • 1. Activity of low-density lipoprotein receptors as estimated from concentrations of apolipoprotein B and C-II in serum.
    Ito H, Naito C, Hayashi H, Kawamura M.
    Clin Chem; 1988 Nov; 34(11):2224-7. PubMed ID: 3141083
    [Abstract] [Full Text] [Related]

  • 2. Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition.
    Bard JM, Parra HJ, Douste-Blazy P, Fruchart JC.
    Metabolism; 1990 Mar; 39(3):269-73. PubMed ID: 2106607
    [Abstract] [Full Text] [Related]

  • 3. Effects of simvastatin on plasma lipids and apolipoproteins in familial hypercholesterolemic swine.
    Hasler-Rapacz J, Kempen HJ, Princen HM, Kudchodkar BJ, Lacko A, Rapacz J.
    Arterioscler Thromb Vasc Biol; 1996 Jan; 16(1):137-43. PubMed ID: 8548414
    [Abstract] [Full Text] [Related]

  • 4. Serum low density lipoprotein cholesterol level and cholesterol absorption efficiency are influenced by apolipoprotein B and E polymorphism and by the FH-Helsinki mutation of the low density lipoprotein receptor gene in familial hypercholesterolemia.
    Gylling H, Aalto-Setälä K, Kontula K, Miettinen TA.
    Arterioscler Thromb; 1991 Jan; 11(5):1368-75. PubMed ID: 1911722
    [Abstract] [Full Text] [Related]

  • 5. Effects of CS-514 (eptastatin), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on serum lipid and apolipoprotein levels in heterozygous familial hypercholesterolemic patients treated by low density lipoprotein (LDL)-apheresis.
    Mabuchi H, Fujita H, Michishita I, Takeda M, Kajinami K, Koizumi J, Takeda R, Takegoshi T, Wakasugi T, Ueda K.
    Atherosclerosis; 1988 Aug; 72(2-3):183-8. PubMed ID: 3145745
    [Abstract] [Full Text] [Related]

  • 6. Effects of CS-514 on serum lipoprotein lipid and apolipoprotein levels in patients with familial hypercholesterolemia.
    Mabuchi H, Kamon N, Fujita H, Michishita I, Takeda M, Kajinami K, Itoh H, Wakasugi T, Takeda R.
    Metabolism; 1987 May; 36(5):475-9. PubMed ID: 3106756
    [Abstract] [Full Text] [Related]

  • 7. Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia.
    Franceschini G, Sirtori M, Vaccarino V, Gianfranceschi G, Chiesa G, Sirtori CR.
    J Lab Clin Med; 1989 Sep; 114(3):250-9. PubMed ID: 2504855
    [Abstract] [Full Text] [Related]

  • 8. Serum lipid and apolipoprotein A and B levels in familial hypercholesterolemia.
    Craig IH, Poulis P, Hill G.
    Aust N Z J Med; 1983 Jun; 13(3):241-6. PubMed ID: 6579937
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Dietary counseling is associated with an improved lipid profile in children with familial hypercholesterolemia.
    Torvik K, Narverud I, Ottestad I, Svilaas A, Gran JM, Retterstøl K, Ellingvåg A, Strøm E, Ose L, Veierød MB, Holven KB.
    Atherosclerosis; 2016 Sep; 252():21-27. PubMed ID: 27494447
    [Abstract] [Full Text] [Related]

  • 13. Lipoprotein Lp(a) in homozygous familial hypercholesterolemia: density profile, particle heterogeneity and apolipoprotein(a) phenotype.
    Guo HC, Chapman MJ, Bruckert E, Farriaux JP, De Gennes JL.
    Atherosclerosis; 1991 Jan; 86(1):69-83. PubMed ID: 1829609
    [Abstract] [Full Text] [Related]

  • 14. The effect of pravastatin in relation to low density lipoprotein receptor activity.
    Hayashi H, Naito C, Ito H, Kawamura M, Miyazaki S.
    Curr Med Res Opin; 1990 Jan; 12(2):100-7. PubMed ID: 2118022
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Apolipoprotein and lipoprotein concentrations in familial apolipoprotein C-II deficiency.
    Breckenridge WC, Alaupovic P, Cox DW, Little JA.
    Atherosclerosis; 1982 Aug; 44(2):223-35. PubMed ID: 7138621
    [Abstract] [Full Text] [Related]

  • 17. Increased hepatic secretion of very-low-density-lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: a stable isotope study.
    Cummings MH, Watts GF, Umpleby M, Hennessy TR, Quiney JR, Sönksen PH.
    Atherosclerosis; 1995 Feb; 113(1):79-89. PubMed ID: 7755658
    [Abstract] [Full Text] [Related]

  • 18. Serum apolipoproteins in heterozygous familial hypercholesterolemia.
    Kajinami K, Mabuchi H, Koizumi J, Takeda R.
    Clin Chim Acta; 1992 Oct 15; 211(1-2):93-9. PubMed ID: 1468157
    [Abstract] [Full Text] [Related]

  • 19. Effects of CS-514 on plasma lipids and lipoprotein composition in hypercholesterolemic subjects.
    Yoshino G, Kazumi T, Iwai M, Iwatani I, Matsuba K, Kasama T, Matsushita M, Otsuki M, Baba S.
    Atherosclerosis; 1988 Jun 15; 71(2-3):95-101. PubMed ID: 3135814
    [Abstract] [Full Text] [Related]

  • 20. Human hepatic low-density lipoprotein receptors: associations of receptor activities in vitro with plasma lipid and apolipoprotein concentrations in vivo.
    Nanjee MN, Miller NE.
    Biochim Biophys Acta; 1989 Apr 03; 1002(2):245-55. PubMed ID: 2495023
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.